As the popularity of weight loss drugs like Ozempic continues to climb, a disturbing pattern is emerging — and it's impacting ...

A GLP-1 oral medication claims to cut the risk of cardiovascular complications, like heart attacks and strokes, by 14% for people with diabetes and heart or kidney disease, per CNBC.

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Hims — the next gen telehealth startup that made waves by taking the eye contact out of erectile dysfunction treatment. Of ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...